Sorafenib has predominant inhibition on tumor growth when IL-6 was knocked out (1026.6±56.0 mm3 versus 673.4±34.0 mm3, P=.027) based on treatment, whereas IFN-α treatment significantly inhibited tumor growth in the HCC derived from HCCLM3-wt cells (4565.2±213.3 mm3 versus 1730.2±169.3 mm3, P =.021). This evidence concerns the gene IL6 and hepatocellular carcinoma.